September 17th 2025
The Phase IIa trial will further explore the EP4 antagonist HTL0039732 in combination with immunotherapy to improve outcomes in resistant solid tumors and expand treatment options.
September 16th 2025
Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone
September 25th 2023The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures
April 28th 2023clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.
AMB-05X Receives EMA PRIME Designation for Treatment of Tenosynovial Giant Cell Tumor
January 20th 2023The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.
Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development
Extrapolating data from adult clinical trials to a pediatric population is a proven method to avoid unnecessary pediatric clinical trials. Representatives of the Pediatric Working Group of the IQ Consortium share case studies that demonstrate how adult clinical trial data can be used to support the dose selection and regimen—or waive the need for a placebo control arm—for pediatric studies.